Literature DB >> 8535394

Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor.

M Tsuchiya1, L Imamura, J B Park, K Kobashi.   

Abstract

We investigated the inhibitory effects of four gastric proton pump inhibitors (PPIs): rabeprazole, a novel benzimidazole PPI, omeprazole, lansoprazole and AG-2000, on the urease activity of Helicobacter pylori (H. pylori). Their 50% inhibitory concentrations (I50s) were found to be 0.29, 5.4, 9.3 and 0.3 microM respectively. Rabeprazole and omeprazole were also potent inhibitors of Jack bean and Proteus mirabilis cellular ureases. The thioether derivative of rabeprazole, one of its metabolites, had no inhibitory effect on H. pylori urease, despite being reported as a more potent inhibitor of H. pylori growth than rabeprazole. The inhibitory effect of rabeprazole was prevented completely and reversed considerably by the addition of sulfhydryl compounds, such as beta-mercaptoethanol, glutathione and dithiothreitol. Moreover, the addition of beta-mercaptoethanol recovered the urease activity inhibited by rabeprazole. From these results, we expected that rabeprazole inhibited H. pylori urease activity by forming disulfide bonds between it and the active site of the enzyme.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8535394     DOI: 10.1248/bpb.18.1053

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  17 in total

1.  In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori.

Authors:  Y Kawakami; T Akahane; M Yamaguchi; K Oana; Y Takahashi; Y Okimura; T Okabe; A Gotoh; T Katsuyama
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group.

Authors:  M L Cloud; N Enas; T J Humphries; S Bassion
Journal:  Dig Dis Sci       Date:  1998-05       Impact factor: 3.199

3.  Isolation and diagnosis of Helicobacter pylori by a new method: microcapillary culture.

Authors:  Adil M Allahverdiyev; Melahat Bagirova; Reyhan Caliskan; Hrisi Bahar Tokman; Hayat Aliyeva; Gokce Unal; Olga Nehir Oztel; Emrah Sefik Abamor; Hilal Toptas; Pelin Yuksel; Fatma Kalayci; Mustafa Aslan; Yusuf Erzin; Kadir Bal; Bekir S Kocazeybek
Journal:  World J Gastroenterol       Date:  2015-03-07       Impact factor: 5.742

Review 4.  Potent gastric acid inhibition in Helicobacter pylori eradication.

Authors:  Javier P Gisbert
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 5.  Rabeprazole: a review of its use in acid-related gastrointestinal disorders.

Authors:  H D Langtry; A Markham
Journal:  Drugs       Date:  1999-10       Impact factor: 9.546

Review 6.  Medicinal plant activity on Helicobacter pylori related diseases.

Authors:  Yuan-Chuen Wang
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

7.  Novel action of gastric proton pump inhibitor on suppression of Helicobacter pylori induced angiogenesis.

Authors:  M Yeo; D-K Kim; S U Han; J E Lee; Y B Kim; Y K Cho; J H Kim; S W Cho; K-B Hahm
Journal:  Gut       Date:  2005-08-26       Impact factor: 23.059

Review 8.  Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders.

Authors:  P Richardson; C J Hawkey; W A Stack
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

9.  Comparison of five-day Helicobacter pylori eradication regimens: rabeprazole-based and omeprazole-based regimens with and without omeprazole pretreatment.

Authors:  Kyoichi Adachi; Tomoyuki Hashimoto; Shunji Ishihara; Hirofumi Fujishiro; Shuichi Sato; Hiroshi Sato; Yuji Amano; Shuzo Hattori; Yoshikazu Kinoshita
Journal:  Curr Ther Res Clin Exp       Date:  2003-07

Review 10.  Helicobacter pylori detection and antimicrobial susceptibility testing.

Authors:  Francis Mégraud; Philippe Lehours
Journal:  Clin Microbiol Rev       Date:  2007-04       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.